Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

SAB Biotherapeutics (SABSW) Interest & Investment Income (2021 - 2025)

Historic Interest & Investment Income for SAB Biotherapeutics (SABSW) over the last 5 years, with Q3 2025 value amounting to $655233.0.

  • SAB Biotherapeutics' Interest & Investment Income rose 13639.77% to $655233.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $867667.0, marking a year-over-year decrease of 4688.85%. This contributed to the annual value of $1.3 million for FY2024, which is 11984.15% up from last year.
  • Latest data reveals that SAB Biotherapeutics reported Interest & Investment Income of $655233.0 as of Q3 2025, which was up 13639.77% from $13562.0 recorded in Q2 2025.
  • Over the past 5 years, SAB Biotherapeutics' Interest & Investment Income peaked at $655233.0 during Q3 2025, and registered a low of $3769.0 during Q3 2021.
  • Its 5-year average for Interest & Investment Income is $141918.1, with a median of $28568.0 in 2023.
  • As far as peak fluctuations go, SAB Biotherapeutics' Interest & Investment Income skyrocketed by 182964.36% in 2024, and later crashed by 9637.92% in 2025.
  • SAB Biotherapeutics' Interest & Investment Income (Quarter) stood at $8544.0 in 2021, then surged by 250.29% to $29929.0 in 2022, then surged by 1517.31% to $484046.0 in 2023, then tumbled by 71.83% to $136374.0 in 2024, then surged by 380.47% to $655233.0 in 2025.
  • Its Interest & Investment Income was $655233.0 in Q3 2025, compared to $13562.0 in Q2 2025 and $62498.0 in Q1 2025.